Company Filing History:
Years Active: 2025
Title: Inventor Spotlight: Andreia Costa and Her Innovative Contributions
Introduction
Andreia Costa, based in Seattle, Washington, is an accomplished inventor known for her groundbreaking work in the field of antibodies and chimeric antigen receptors. With a focus on receptor tyrosine kinase-like orphan receptor 1 (ROR1), Andreia's innovative contributions hold promise for advancements in cancer therapy.
Latest Patents
Andreia Costa holds a pivotal patent titled "Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)." This patent details the development of ROR1-binding molecules, particularly human antibodies specific to ROR1, including antibody fragments. The disclosure emphasizes the creation of recombinant receptors, such as chimeric antigen receptors (CARs) containing these antibodies or fragments. It also discusses polynucleotides encoding these antibodies, along with genetically engineered cells containing ROR1-binding proteins and receptors, illustrating their potential in adoptive cell therapy.
Career Highlights
Andreia is currently engaged with Juno Therapeutics GmbH, a leader in cell therapy innovation. Her work at Juno Therapeutics exemplifies her dedication to translating her inventive ideas into real-world medical applications, aimed at improving therapeutic options for patients battling cancer.
Collaborations
Throughout her career, Andreia has collaborated with talented colleagues, including Rupesh Amin and Jenna Bailey, further enriching her work with diverse perspectives and expertise. These collaborations illustrate the importance of teamwork in driving innovation forward.
Conclusion
Andreia Costa stands out as a significant inventor in the realm of biotechnology. With her patent focusing on ROR1-targeted therapies, she exemplifies how innovative ideas can lead to transformative solutions in the medical field. As she continues her journey at Juno Therapeutics GmbH, the potential for her work to impact cancer treatments remains promising and inspiring.